Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Japan Pediatric Society's Scientific Meeting
May 22, 2006
- Mr Nogimori Wants to Make
May 22, 2006
- REGULATORY NEWS IN BRIEF
May 22, 2006
- SURVEY 3 articles
May 22, 2006
- NEW PRODUCTS
May 22, 2006
- Tanabe Seiyaku Announces
May 22, 2006
- Eisai Starts PI Trial for
May 22, 2006
- Daiichi Sankyo: Olmesartan
May 22, 2006
- CPHI JAPAN 2006
May 22, 2006
- Banyu to Focus on Basic Research,
May 15, 2006
- R&D NEWS IN BRIEF
May 15, 2006
- New Drug Improves Quality of Sleep: Rohto
May 15, 2006
- Abbott Acquires Guidant Vascular Business
May 15, 2006
- Astellas Licenses Anemia
May 15, 2006
- Morimoto-Iyaku Establishes
May 15, 2006
- Novartis Pharma Integrates Marketing Systems
May 15, 2006
- MEDICAL DEVICE NEWS IN BRIEF
May 15, 2006
- BUSINESS NEWS IN BRIEF
May 15, 2006
- ANNUAL BUSINESS RESULTS
May 15, 2006
- ANNUAL BUSINESS RESULTS
May 15, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…